Benign Prostatic Hyperplasia (BPH) Clinical Trial
Official title:
Holmium Laser Enucleation of Prostate in Management of Benign Prostatic Hyperplasia Patients With Predominant Voiding Versus Storage Lower Urinary Tract Symptoms: A Comparative Retrospective Study
Comparison in outcomes of a minimally invasive surgical modality (Holmium Laser Enucleation of Prostate) in management of voiding versus storage lower urinary tract symptoms associated with Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is a common condition affecting a large number of men over the age of 50 years and is the major cause of the highly prevalent lower urinary tract symptoms (LUTS) in men of this age group that often necessitate surgical intervention. The LUTS associated with BPH are generally divided into voiding symptoms (slow stream, splitting or spraying, intermittency, hesitancy, straining, terminal dribbling) and storage symptoms (day-time urinary frequency, nocturia, urgency, urinary incontinence). These LUTS are among the most common clinical complaints in adult men with reported increasing prevalence with aging. The storage LUTS may also be termed overactive bladder (OAB) symptoms and are largely encompassed by the term "overactive bladder syndrome" (OABS). While the voiding symptoms are usually more prevalent, the storage symptoms are almost always more bothersome. Associated with a significant burden on both patients and society, these LUTS also have a major impact on patients' quality of life (QoL). As such, The American Urological Association (AUA) has developed the International Prostate Symptom Score (IPSS) as one of the most reliable tools to evaluate the severity of LUTS associated with BPH which, in turn, plays a major role in determining the most appropriate treatment option for BPH. After being the preferred surgical treatment for BPH patients for more than 30 years, transurethral resection of prostate (TURP) has been replaced by holmium laser enucleation of prostate (HoLEP) as the gold standard surgical treatment for BPH. Introduced in 1995, HoLEP is a minimally invasive surgical procedure that has become the first line treatment of BPH as it provides both effective and safe surgical treatment option for BPH without any size limitation, although at the expense of occasional complications. HoLEP has the advantage of enucleating the enlarging BPH adenoma without destroying the bladder neck thus relieving bladder outflow obstruction (BOO) immediately, safely, and effectively. Although improvement in both storage and voiding LUTS has been demonstrated after either medical treatment with an alpha-blocker or a 5-alpha-reductase inhibitor or surgical treatment with TURP for BPH patients, few studies have been made to measure the outcomes of HoLEP in BPH-related voiding and/or storage LUTS. We performed our study with the aim to evaluate and compare the effectiveness and safety of HoLEP in relieving either voiding or storage LUTS in BPH patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03052049 -
Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
|
N/A | |
| Recruiting |
NCT04757116 -
Post-Market Study to Assess iTind Safety in Comparison to UroLift
|
N/A | |
| Completed |
NCT03460873 -
Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate
|
||
| Completed |
NCT01218243 -
An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
|
Phase 2 | |
| Completed |
NCT01566292 -
Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT00407953 -
PROLIEVE® Post-Marketing Study TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
|
Phase 4 | |
| Completed |
NCT03191734 -
French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
|
N/A | |
| Recruiting |
NCT04838769 -
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
|
N/A | |
| Completed |
NCT03856242 -
Benign Prostatic Hyperplasia and Ischemic Heart DIsease
|
Phase 4 | |
| Completed |
NCT04032067 -
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
| Completed |
NCT02505919 -
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
|
N/A | |
| Completed |
NCT02855892 -
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
|
Phase 2 | |
| Completed |
NCT02145208 -
Study to Assess the Efficacy of Medi-Tate iTind Device
|
N/A | |
| Completed |
NCT00970632 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
|
Phase 3 | |
| Recruiting |
NCT02592473 -
Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia
|
N/A | |
| Completed |
NCT00945490 -
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
|
Phase 3 | |
| Completed |
NCT00759135 -
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
|
Phase 2 | |
| Completed |
NCT00224107 -
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
|
Phase 3 | |
| Recruiting |
NCT04648176 -
Application of MOSES Technology in BPH
|
N/A | |
| Terminated |
NCT00651807 -
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
|
Phase 2 |